Study #2016-0785
A phase II Study of Venetoclax (ABT-199) consolidation for patients currently receiving ibrutinib or acalabrutinib for High-risk CLL
MD Anderson Study Status
Enrolling
Treatment Agent
Ibrutinib, Venetoclax, Acalabrutinib
Description
This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy. The study will estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable CLL after receiving ibrutinib or acalabrutinib for at least 12 months and who have high risk CLL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Lymphocytic Leukemia
Study phase:
Phase II
Physician name:
Alessandra Ferrajoli
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.